MF
NBIX icon

Magnetar Financial’s Neurocrine Biosciences NBIX Stock Holding History

Magnetar Financial’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-29,192
Closed -$4.14M – 1304
2025
Q4 		$4.14M Sell
29,192
-4,879
-14% -$707K 0.04% 221
2025
Q3 		$4.78M Buy
+34,071
New +$4.62M 0.03% 239
2025
Q2 		– Sell
-9,935
Closed -$1.1M – 1047
2025
Q1 		$1.1M Buy
+9,935
New +$1.26M 0.01% 327
2024
Q4 		– Sell
-2,732
Closed -$315K – 730
2024
Q3 		$315K Buy
+2,732
New +$375K 0.01% 398
2020
Q4 		– Sell
-19,009
Closed -$1.83M – 837
2020
Q3 		$1.83M Buy
+19,009
New +$2.2M 0.03% 266
2020
Q1 		– Sell
-2,491
Closed -$268K – 577
2019
Q4 		$268K Buy
+2,491
New +$261K 0.01% 459

Other funds holding NBIX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Magnetar Financial's NBIX Position: Q1 2026 in Review

Magnetar Financial sold out of Neurocrine Biosciences (NBIX) in Q1 2026, closing a stake of 29,192 shares — an estimated $4.14M sold.

Magnetar Financial first reported a position in NBIX in Q4 2019 and held it in 6 quarters. The position peaked at $4.78M in Q3 2025. 694 funds tracked by Wall St. Rank hold NBIX as of Q1 2026.

  • Magnetar Financial reported no remaining Neurocrine Biosciences position as of Q1 2026 after selling out during the quarter.
  • Magnetar Financial sold 29,192 Neurocrine Biosciences shares in Q1 2026, an estimated $4.14M.
  • Magnetar Financial first reported a position in Neurocrine Biosciences in Q4 2019 and held it in 6 quarters.
  • Magnetar Financial's Neurocrine Biosciences position peaked at $4.78M in Q3 2025.
  • 694 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q1 2026.

Based on Magnetar Financial's 13F filing for Q1 2026, filed 13 May 2026.